Biogen
Executive Summary
Purchase of 50% interest in West German firm Bioferon Biochemische Substanzen aimed at facilitating entry of Biogen's gamma interferon into West German and other markets, according to Biogen. Bioferon, which was a wholly owned subsidiary of Rentschler Pharmaceutical (West Germany), markets a beta interferon product, Fiblaferon, in West Germany for life threatening viral infections. Biogen says Fiblaferon, produced through traditional technologies, is "the first interferon product in the world to receive full regulatory approval.".